These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17485743)

  • 1. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB; Kennedy EM
    Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of risk-management plans.
    Meltzer D
    Health Aff (Millwood); 2007; 26(3):681-3. PubMed ID: 17485744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
    Gentry G
    Food Drug Law J; 2009; 64(3):441-58. PubMed ID: 19999637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug safety proposals and the intrusion of federal regulation into patient freedom and medical practice.
    Gottlieb S
    Health Aff (Millwood); 2007; 26(3):664-77. PubMed ID: 17485742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J; Grenade LL; Kwon H; Avigan M
    Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyberpharmacies and the role of the US Food And Drug Administration.
    Henney JE
    J Med Internet Res; 2001; 3(1):E3. PubMed ID: 11720945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label pharmaceutical use: balancing information, risks, and benefits.
    Kozma CM
    Manag Care Interface; 2004 Jan; 17(1):29-30. PubMed ID: 15035597
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 13. Should you let the FDA decide what drugs you pay for?
    Dutton G
    Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use.
    Meadows WA; Hollowell BD
    Int J Impot Res; 2008; 20(2):135-44. PubMed ID: 18004389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quandary of compounding for MCOs: administrative costs, risks, and waste.
    Kaye T
    Manag Care; 2003 Jan; 12(1):42-8. PubMed ID: 12575510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
    Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
    Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Court is asked to invalidate the Food and Drug Administration's (FDA's) "pediatric rule".
    Maloney DM
    Hum Res Rep; 2002 Dec; 17(12):8. PubMed ID: 12731500
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA reform: new Senate bill. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.